Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma.
Fishbein L, Del Rivero J, Else T, Howe JR, Asa SL, Cohen DL, Dahia PLM, Fraker DL, Goodman KA, Hope TA, Kunz PL, Perez K, Perrier ND, Pryma DA, Ryder M, Sasson AR, Soulen MC, Jimenez C. Fishbein L, et al. Among authors: pryma da. Pancreas. 2021 Apr 1;50(4):469-493. doi: 10.1097/MPA.0000000000001792. Pancreas. 2021. PMID: 33939658
Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma.
Makvandi M, Samanta M, Martorano P, Lee H, Gitto SB, Patel K, Groff D, Pogoriler J, Martinez D, Riad A, Dabagian H, Zaleski M, Taghvaee T, Xu K, Lee JY, Hou C, Farrel A, Batra V, Carlin SD, Powell DJ Jr, Mach RH, Pryma DA, Maris JM. Makvandi M, et al. Among authors: pryma da. Commun Biol. 2022 Nov 17;5(1):1260. doi: 10.1038/s42003-022-04209-8. Commun Biol. 2022. PMID: 36396952 Free PMC article.
SDHB mutation carriers with malignant pheochromocytoma respond better to CVD.
Fishbein L, Ben-Maimon S, Keefe S, Cengel K, Pryma DA, Loaiza-Bonilla A, Fraker DL, Nathanson KL, Cohen DL. Fishbein L, et al. Among authors: pryma da. Endocr Relat Cancer. 2017 Aug;24(8):L51-L55. doi: 10.1530/ERC-17-0086. Epub 2017 May 31. Endocr Relat Cancer. 2017. PMID: 28566531 No abstract available.
Efficacy of Peptide Receptor Radionuclide Therapy in a United States-Based Cohort of Metastatic Neuroendocrine Tumor Patients: Single-Institution Retrospective Analysis.
Katona BW, Roccaro GA, Soulen MC, Yang YX, Bennett BJ, Riff BP, Glynn RA, Wild D, Nicolas GP, Pryma DA, Teitelbaum UR, Metz DC. Katona BW, et al. Among authors: pryma da. Pancreas. 2017 Oct;46(9):1121-1126. doi: 10.1097/MPA.0000000000000919. Pancreas. 2017. PMID: 28902781 Free PMC article.
Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma.
Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, Kostakoglu L, Serafini AN, Pampaloni MH, Jensen J, Armor T, Lin T, White T, Stambler N, Apfel S, DiPippo VA, Mahmood S, Wong V, Jimenez C. Pryma DA, et al. J Nucl Med. 2019 May;60(5):623-630. doi: 10.2967/jnumed.118.217463. Epub 2018 Oct 5. J Nucl Med. 2019. PMID: 30291194 Free PMC article. Clinical Trial.
NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy.
Hope TA, Bodei L, Chan JA, El-Haddad G, Fidelman N, Kunz PL, Mailman J, Menda Y, Metz DC, Mittra ES, Pryma DA, Reidy-Lagunes DL, Singh S, Strosberg JR. Hope TA, et al. Among authors: pryma da. J Nucl Med. 2020 Feb;61(2):222-227. doi: 10.2967/jnumed.119.240911. J Nucl Med. 2020. PMID: 32015164 Free PMC article. No abstract available.
Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor Cohort.
Heckert JM, Kipnis ST, Kumar S, Botterbusch S, Alderson A, Bennett B, Creamer C, Eads JR, Soulen MC, Pryma DA, Mankoff DA, Metz DC, Katona BW. Heckert JM, et al. Among authors: pryma da. Oncologist. 2020 Jul;25(7):572-578. doi: 10.1634/theoncologist.2019-0743. Epub 2020 Mar 6. Oncologist. 2020. PMID: 32141667 Free PMC article.
132 results